GENSIGHT BIOLOGICS: New publication re-iterates the view towards EMA approval | | EUR14
GENSIGHT BIOLOGICS - | EUR14 (+110%)New publication re-iterates the view towards EMA approval
New publication re-iterates key thesis points into EMA approval of LUMEVOQ
What’s new?
Attractive setup into approval and REFLECT data in ‘21e, Re-iterate BUY and EUR 14 TP
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.